Evaluation of MK-1484 Monotherapy and Combination with Pembrolizumab in Adults with Advanced or Metastatic Solid Tumors

The primary objective of this clinical trial is to evaluate the efficacy and safety of **MK-1484** administered alone and in combination with **pembrolizumab** in adults with **advanced or metastatic solid tumors**. This study aims to determine the therapeutic potential and tolerability of the investigational drug regimen in a population with limited treatment options, thereby addressing a significant clinical need in oncology. The trial seeks to provide insights into the potential benefits of combining MK-1484 with pembrolizumab, a well-established immune checkpoint inhibitor, to enhance anti-tumor activity and improve patient outcomes.

The clinical trial involves a total of **80 participants** diagnosed with **advanced or metastatic solid tumors**. The study population includes both male and female subjects, with an age range encompassing adults and older adults. Participants were selected to include a vulnerable population, although specific inclusion or exclusion criteria were not provided. The general health status of the participants is characterized by the presence of advanced or metastatic solid tumors, indicating a significant health challenge. Lifestyle considerations such as diet, physical activity, or habits were not specified in the available data. The selection process aimed to ensure a representative sample of individuals affected by the specified medical condition, although further details on the selection criteria were not disclosed by the sponsor.

The clinical trial is designed to evaluate the safety and efficacy of **MK-1484** administered alone and in combination with pembrolizumab in adults with **advanced or metastatic solid tumors**. This study is a Phase 1 trial, characterized by a randomized, double-blind, and controlled design. The trial is expected to commence recruitment on July 11, 2022, and is projected to conclude by May 29, 2026. Participants will be involved in the study for a duration that aligns with the trial's timeline, subject to individual response and tolerance to the treatment.

The sequence of study visits begins with an inclusion visit, also known as the screening visit, where potential participants are assessed for eligibility based on predefined criteria. Following successful screening, participants will undergo a series of follow-up visits at regular intervals to monitor their response to the treatment and to ensure their safety. These visits will include comprehensive assessments such as physical examinations, laboratory tests, and imaging studies as required. The end-of-study visit will mark the conclusion of a participant's involvement, during which final evaluations will be conducted to gather data on the long-term effects of the treatment.

Participants may be subject to early termination from the study if they experience adverse effects that compromise their safety, if they withdraw consent, or if they fail to comply with the study protocol. The trial's methodology is structured to ensure rigorous data collection and analysis, contributing to the understanding of the investigational drug's potential benefits and risks in treating advanced or metastatic solid tumors.

The clinical trial involves the administration of an **experimental medication**. However, specific details regarding the name, pharmaceutical form, dosage, route, and frequency of administration of the experimental medication are not provided in the available data. The trial documentation does not specify whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. Additionally, there is no information on the maximum daily dose, total dose, or treatment period for the experimental medication.

In this clinical trial, there is no mention of any **non-experimental treatments** such as standard-of-care therapy, placebo, or comparator treatment being used. The data does not provide details on any additional relevant information about drug administration, dosing schedules, or participant compliance monitoring. The absence of these details suggests that the trial documentation may be incomplete or that such information is not applicable to this particular study.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an early stage of clinical research primarily focused on safety and dosage. The estimated recruitment start date for the trial is July 11, 2022, with an anticipated end date of May 29, 2026. Although specific efficacy parameters such as primary or secondary endpoints are not detailed, Phase 1 trials typically involve initial assessments of therapeutic effects alongside safety evaluations. The trial will likely employ standard methodologies for data collection and analysis, consistent with Phase 1 objectives, to ensure reliable and valid results. The absence of detailed endpoints suggests a focus on exploratory outcomes, which may include preliminary efficacy signals to guide future research phases.